SCHEMBL1814229

SCHEMBL1814229

COc1ccc(CCNC(=O)c2ccccc2Br)cc1OC

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
MAPT P10636 1/20 0.60
LMNA P02545 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
NAMPT P43490 2/20 0.60
ABCG2 Q9UNQ0 1/20 0.60
PKM P14618 1/20 0.60
ALDH1A1 P00352 2/20 0.59
GAA P10253 1/20 0.59
CA1 P00915 2/20 0.59
CA2 P00918 2/20 0.59
CA9 Q16790 2/20 0.59
CA12 O43570 1/20 0.59
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6267575 0.88 CYP1A2 (0.65) CYP1A2CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL10107716 0.87 APEX1 (0.66) LMNAL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL1812144 0.86 MEN1 (0.65) CYP1A2CYP3A4CYP2C9CYP2C19LMNA
SCHEMBL1813399 0.85 GAA (0.66) CYP1A2CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL28475160 0.85 NAMPT (0.63) CYP1A2CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL10333227 0.83 KMT2A (0.72) CYP1A2CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL27380778 0.82 RAB9A (0.60) ALDH1A1CA1CA2CA9NPC1
SCHEMBL29356619 0.82 ALDH1A1 (0.77) MAPTMEN1KMT2ANAMPTPKM
SCHEMBL6270935 0.82 ALDH1A1 (0.77) MAPTMEN1KMT2ANAMPTPKM
SCHEMBL26368509 0.81 KMT2A (0.65) CYP1A2CYP3A4CYP2C19MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314269-B2 N-(1-methyl-2phenylethyl)benzamide derivatives BAYER CROPSCIENCE AG (DE) 2012-11-20 US claimed
US-20110237678-A1 N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2011-09-29 US claimed
US-20090156682-A1 N-(1-Methyl-2Phenylethyl)Benzamide Derivatives BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-06-18 US claimed
EP-1960350-A1 NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE SA (FR) 2008-08-27 EP claimed
WO-2007060162-A1 NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE SA (FR) 2007-05-31 WO claimed
US-8314269-B2 N-(1-methyl-2phenylethyl)benzamide derivatives BAYER CROPSCIENCE AG (DE) 2012-11-20 US disclosed
US-20110237678-A1 N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2011-09-29 US disclosed
US-7951973-B2 N-(1-methyl-2Phenylethyl)benzamide derivatives BAYER CROPSCIENCE AG (DE) 2011-05-31 US disclosed
US-20090156682-A1 N-(1-Methyl-2Phenylethyl)Benzamide Derivatives BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-06-18 US disclosed
EP-1960350-A1 NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE SA (FR) 2008-08-27 EP disclosed
WO-2007060162-A1 NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE SA (FR) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156682-A1 N-(1-Methyl-2Phenylethyl)Benzamide Derivatives CYP51A1, CYP1A2, CYP1A1 CYP1A2 2/4885CYP3A4 20/4885CYP2C9 36/4885
US-20110237678-A1 N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES CYP51A1, CYP1A2, CYP1A1 CYP1A2 2/4885CYP3A4 16/4885CYP2C9 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.